Risks of paxlovid in a heart transplant recipient.
J Heart Lung Transplant
; 2022 Sep 08.
Artículo
en Inglés
| MEDLINE | ID: covidwho-2235897
ABSTRACT
The burden of morbidity and mortality from SARS-CoV-2 infection is especially significant in heart transplant patients who are at higher risk for poor outcomes owing to immunosuppression, blunted response to vaccination, and multiple comorbid conditions. Over the last 3 years the therapeutic landscape for COVID-19 has evolved and our drug armamentaria continues to expand. With these advancements comes a time of great hope to mitigate significant illness from SARS - CoV - 2 infection. However, as with many emerging frontiers, the administration of novel therapeutics to a complex patient population remains challenging. We present a patient case encountered at our institution that highlights the need for increased awareness of nuances while managing COVID-19 infection in a heart transplant recipient.
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Tipo de estudio:
Estudio pronóstico
Tópicos:
Vacunas
Idioma:
Inglés
Asunto de la revista:
Cardiología
/
Trasplante
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS